OBJECTIVE A genome-wide association study (GWAS) in Pima Indians (n = 413) identified variation in the ataxin-2 binding protein 1 gene (A2BP1) that was associated with percent body fat. On the basis of this association and the obese phenotype of ataxin-2 knockout mice, A2BP1 was genetically and functionally analyzed to assess its potential role in human obesity.
RESEARCH DESIGN AND METHODS Variants spanning A2BP1 were genotyped in a population-based sample of 3,234 full-heritage Pima Indians, 2,843 of whom were not part of the initial GWAS study and therefore could serve as a sample to assess replication. Published GWAS data across A2BP1 were additionally analyzed in French adult (n = 1,426) and children case/control subjects (n = 1,392) (Meyre et al. Nat Genet 2009;41:157–159). Selected variants were genotyped in two additional samples of Caucasians (Amish, n = 1,149, and German children case/control subjects, n = 998) and one additional Native American (n = 2,531) sample. Small interfering RNA was used to knockdown A2bp1 message levels in mouse embryonic hypothalamus cells.
RESULTS No single variant in A2BP1 was reproducibly associated with obesity across the different populations. However, different variants within intron 1 of A2BP1 were associated with BMI in full-heritage Pima Indians (rs10500331, P = 1.9 × 10−7) and obesity in French Caucasian adult (rs4786847, P = 1.9 × 10−10) and children (rs8054147, P = 9.2 × 10−6) case/control subjects. Reduction of A2bp1 in mouse embryonic hypothalamus cells decreased expression of Atxn2, Insr, and Mc4r.
CONCLUSIONS Association analysis suggests that variation in A2BP1 influences obesity, and functional studies suggest that A2BP1 could potentially affect adiposity via the hypothalamic MC4R pathway.
Recent large-scale genome-wide association studies (GWASs) have uncovered common variants in several loci associated with obesity in multiple populations (1–7). Most of these studies have been done in populations of European ancestry. Additional GWASs in diverse ethnic groups could confirm previously identified obesity-associated genes, identify novel ethnic-specific susceptibility genes, or identify ethnic-specific variation within a previously identified gene. Several examples exist of common variation in a gene contributing to obesity in one population but unique, rare variation contributing to obesity in a different population. For example, a common obesity-associated variant, rs17782313, near MC4R has been widely replicated in Europeans (3,5,6), but this same variant is nearly monomorphic for the Caucasian nonrisk allele (T allele) in full-heritage Pima Indians, whereas rare coding variants in MC4R, one of which is a novel frameshift mutation that has not been reported in other populations, do contribute to obesity in Pima Indians (8,9). Similarly, a common obesity-associated variant in SIM1 has been reproducibly associated with obesity in Native Americans but not French Caucasians (10), whereas both rare deletions and rare missense variants in SIM1 have been reported to be associated with severe obesity in Caucasians (11–19).
To search for loci that may be important in determining obesity in Pima Indians, we recently completed a GWAS using the Affymetrix 100K genotyping array in a group of 413 nondiabetic full-heritage Pima Indians who were phenotyped for various measures of body composition including percent body fat. Our most significant association with percent body fat was in the A2BP1 gene (rs10500331, P = 6.6 × 10−6), which encodes for the ataxin-2 binding protein 1 (also known as FOX-1) and is involved in tissue-specific alternative splicing (20). In addition to containing RNA-binding motifs, A2BP1 also interacts with ataxin-2 (ATXN2) (21), a protein thought to be involved with RNA metabolism (22). ATXN2 has been implicated in the neurodegenerative disorder spinocerebellar ataxia type 2 (SCA2) (22), and hyperphagia and obesity are two major clinical features reported in an Egyptian family with SCA2 (23). Consistent with this observation, ataxin-2 knockout mice (Sca−/−) are reported to be much more obese than their wild-type littermates when both are fed a high-fat diet (24,25). Therefore, based on the genetic associations with percent body fat in our GWAS and the obese phenotype of the Sca2−/− mouse, we studied A2BP1 as a potential candidate gene for human obesity.
RESEARCH DESIGN AND METHODS
Subjects and phenotypes.
Descriptions of subjects used in the association analyses are shown in Table 1. The GWAS sample consists of 413 nondiabetic, full-heritage Pima Indian volunteers who had been metabolically characterized as inpatients in our Clinical Research Center and were informative for quantitative traits related to obesity and diabetes, including percent body fat and BMI. Some of these healthy, metabolically characterized subjects were first-degree relatives (413 subjects came from 264 sibships, 98 of whom consisted of ≥2 siblings). Body composition was estimated by underwater weighing until January 1996 and by dual-energy X-ray absorptiometry (DPX-1, Lunar Radiation Corp, Madison, WI) thereafter. A conversion equation derived from comparative analyses was used to make estimates of body composition equivalent between the two methods (26). Associations were further assessed in a full-heritage Pima Indian population-based sample (full-heritage Pima population, n = 3,234) derived from our longitudinal study of the etiology of type 2 diabetes in the Gila River Indian Community in Central Arizona (27). Most of the residents are Pima Indians, and many are related to one another. The study includes biennial exams performed on individuals who provide informed consent and include measurements of height, weight, and a 75-g oral glucose tolerance test, where diabetes was diagnosed according to 1997 American Diabetes Association criteria. BMI was calculated as weight (kg)/height (m2). Analysis of BMI was restricted to all exams after the subjects reached the age of 15 years (number of BMI measurements for all 3,234 subjects = 15,722). Of these 3,234 subjects, 391 had been included in the GWAS sample; therefore, to assess independent replication of the GWAS associations, the 2,843 “nonoverlapping with GWAS” subjects were additionally analyzed separately (number of BMI measurements for the 2,843 subjects = 13,751). Selected variants were genotyped in a second population-based sample from our study of the Gila River Indian Community, which consisted of all of the remaining longitudinally studied individuals who had a BMI measure after the age of 15 years and a DNA sample available for genotyping (n = 2,531). In contrast to the full-heritage Pima sample, no restrictions on heritage were applied for subjects in this second sample. The subjects in this “mixed-heritage,” predominately Native American sample (number of BMI measurements for 2,531 subjects = 6,973) self-reported their heritage as, on average, ½ Pima Indian and ¾ Native American, with 59 individuals reporting no Native American heritage.
The Old Order Amish subjects (n = 1,149) were from the Amish Family Diabetes Study (28). The German school children consisted of 715 lean subjects (control subjects, mean age = 11.7 ± 2.7 years, BMI between 16th and 85th percentile) and 283 obese subjects (case subjects, mean age = 11.5 ± 3.7 years, BMI > 90th percentile) (29). French adult and children case/control subjects from a GWAS for obesity have been described elsewhere (1). Briefly, case children were in the 97th age-and sex-specific percentile of BMI and had evidence of familial obesity, and control children had a BMI < 90th percentile. Case adults had a BMI ≥ 40 kg/m2 and evidence of familial obesity, and control adults had a repeated BMI measure of <25 kg/m2.
Genotyping for GWAS data.
Subjects in the Pima GWAS were genotyped using the Affymetrix 100K Human Mapping Array (Affymetrix, Santa Clara, CA), and the methodology and quality control assessment have been described previously (27). Published genotypic data across A2BP1 for the French Caucasian adults and children were obtained from the Illumina Human CNV370 Duo Array (1).
Sequencing and genotyping.
DNA samples from 24 full-heritage Pima Indians (12 obese/12 nonobese), who were not first-degree relatives, were sequenced to identify novel variants in A2BP1. Overlapping primers were designed to sequence all 16 exons, 5′- and 3′-untranslated regions, and 2 kb of the adjacent 5′-region. Sequencing reactions were performed using a Big Dye Terminator v1.1 cycle sequencing kit (Applied Biosystems, Foster City, CA) and run on an automated DNA capillary sequencer (model 3730xl, Applied Biosystems, Foster City, CA). Sequence information for the two novel variants (A2BP1E3 and A2BP1E15) is provided at the bottom of supplementary Table 2, available in an online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db09-1604/DC1. Linkage disequilibrium plots (D′ and r2) were generated using the Haploview program (Haploview, http//:www.broad.mit.edu/mpg/haploview). Genotyping of the full-heritage Pima Indian and mixed-heritage samples was performed using SNPlex (Applied Biosystems, Foster City, CA) on an automated DNA capillary sequencer (model 3730xl, Applied Biosystems, Foster City, CA). Selected variants were genotyped in the Old Order Amish subjects (28) and German school children (29) using Taqman genotyping assays (Applied Biosystems, Foster City, CA).
Statistical analyses were performed using the SAS program of the SAS Institute (Cary, NC). For the GWAS data, linear regression models were used to assess the association between genotype and percent body fat or BMI, adjusting for covariates including age and sex. The logarithm of BMI was used to reduce skewness. The generalized estimating equations procedure was used to account for family membership because some subjects were siblings. The method of genomic control was used to “correct” the P values to their expected distribution. As described by Devlin et al., the mean χ2 value was used to obtain the inflation parameter (λ) and the corrected P value was calculated from an F test with one degree of freedom in the numerator and the number of markers in the denominator (30). The λ was 1.14 for percent body fat and 1.16 for BMI. In addition, to provide a test that is robust to stratification (minimizes the false positive rate), a modification of the method described by Abecasis et al. was used where the associations are partitioned into between- and within-family components (31); for the present analyses, these components were represented, respectively, by the mean number of risk alleles for the sibship and each individual's departure from this mean. For the longitudinally studied population-based samples, the association between genotype and BMI was examined using all of the BMI measurements for each individual measured after the age of 15 years. In these analyses, a linear mixed model (PROC MIXED) was fitted that included genotype as a fixed effect along with age, sex, birth year, diabetic status, and duration of diabetes as covariates. For examinations at which an individual did not have diabetes, the duration variable was coded as “0”; this approach can account for the observation that BMI tends to decline after the diagnosis of diabetes in this population (32). In addition, the model included random effects representing sibship (to account for the fact that some individuals were siblings) and individual (to account for multiple examinations within an individual). An autoregressive correlation structure was used to model the relationship between multiple examinations within an individual. To reduce computation time, the random effects were estimated once in the absence of genotypic effects and in subsequent analyses were held fixed at the values estimated in the full data. The likelihood ratio test was used to assess statistical significance. In the second population-based sample where many individuals were of mixed-heritage, the individual estimate of Indian admixture was also used as a covariate. These estimates were derived by using a published method (33) from 32 markers selected for having large differences in allele frequency between Native Americans and Caucasians (34). Tests for genotypic association were undertaken assuming an additive effect of the alleles on the phenotype. To assess the evidence for association when both population-based samples of Native Americans were combined, the coefficients for the genotypic effect were combined and weighted by the inverse of their variance estimates (35). P values were not adjusted for multiple comparisons.
The association of BMI versus genotypes in the Amish sample was performed using the generalized linear model after adjusting for age, sex, and family membership. Comparison of genotype frequencies between the lean and obese German school children case/control subjects were performed by logistic regression analysis adjusted for age, sex, pubertal stage, and height. Because parameter estimates for case subject–control subject and quantitative trait analyses are not comparable, results were combined across studies using Stouffer's method of combining P values (36).
Tissue profiling for A2BP1.
Primers located in exons 5 and 6 of the A2BP1 transcript (accession ID AF107203) were used to amplify cDNA from the following human tissues: adipose, hypothalamus, pituitary (BD Marathon-Ready cDNA; BD Bioscience/Clontech), brain, skeletal muscle, heart, fetal liver, adult liver, kidney, pancreas (BD Human MTC Multiple Tissue cDNA Panels I and II; BD Bioscience/Clontech), pancreatic islets (kindly provided by Dr. Lorella Marcelli at Joslin Diabetes Center), and preadipocytes isolated from Pima Indians. PCR products were sequenced to confirm that they encoded A2BP1.
Isolation of preadipocytes and synthesis of cDNA.
Subjects for adipose tissue biopsies were admitted as inpatients to our Clinical Research Center and, after an overnight fast, underwent a subcutaneous abdominal needle biopsy under local anesthesia with 1% lidocaine. Collagenase digestion of the subcutaneous abdominal adipose tissue biopsy samples was done as previously described (37,38).
Cell culture and A2bp1 knockdown.
Mouse N-41 hypothalamus cell line (Cat. No. CLU121) was purchased from Cellutions Biosystems, Inc. (Burlington, ON, Canada) and used within 10 passages of the original vial. Cells were grown in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS (ATCC, Manassas, VA) and 20 mmol/l glucose (EM Science, Cincinnati, OH) at 37°C with 5% CO2. Prior to small interfering RNA (siRNA) transfection, N-41 cells were seeded in six-well plates at a density of ∼105 cells per well. For each transfection, 9 μl of siPORT Amine Transfection Agent (Silencer siRNA Transfection II Kit, Ambion, Austin, TX) and A2bp1 siRNA were resuspended separately in 100 μl of GIBCO Opti-MEM I medium (Invitrogen, Carlsbad, CA). After incubating for 10 min at room temperature, the siRNA and transfection agent mixtures were combined (total 200 μl) and siRNA/transfection agent complexes were allowed to form for 10 min. After the 10 min incubation, the 200 μl transfection mixture was added to each well, and after 8–24 h, the media was replaced. The transfected cells were incubated for 48 h and then harvested for RNA extraction. SiRNA (sense, 5′-GAUUUGGUUUCGUAACUUUtt-3′ and antisense, 5′-AAAGUUACGAAACCAAAUCcc-3′; assay ID si114129) targeting the mouse A2bp1 transcript and negative control (scrambled) siRNA (assay ID 4618G) were purchased from Ambion (Austin, TX). Total RNA was extracted from the transfected N-41 cells using an RNeasy Mini Kit (Qiagen, Valencia, CA). To remove any residual DNA, the purified RNA was treated with DNase using an RNase-free DNase set (Qiagen, Valencia, CA). First-strand cDNA was synthesized using an Ambion RT-for-PCR kit (Austin, TX). Gene expression levels for mouse A2bp1, Atxn2, Insr, Mc4r, Lepr, and Npy1r were quantified by real-time PCR using predesigned gene expression assays (assay IDs: A2bp1, Mm00480615_m1; Atxn2, Mm00485932_m1; Insr, Mm00439693_m1; Mc4r, Mm00457483_s; Lepr, Mm00440181_m1; and Npy1r, Mm00650798_g1; Applied Biosystems, Foster City, CA). Real-time PCR was performed using an ABI-7700 sequence detection system (Applied Biosystems, Foster City, CA). Assays were performed in replicates of six, and the mean values were used to calculate expression levels using the relative standard curve method. Glyceraldehyde-3-phosphate dehydrogenase (Gapdh, assay ID Mm03302249_g1, Applied Biosystems, Foster City, CA) was used as the endogenous control to obtain normalized values. Each experiment was independently repeated three times. Student t test was used to compare the means for cells transfected with A2bp1 siRNA with those transfected with control siRNA.
Association analyses among 413 metabolically characterized, nondiabetic full-heritage Pima Indians who had been genotyped using the Affymetrix 100K Human Mapping Array identified rs10500331 as the strongest genome-wide signal for percent body fat (P = 6.6 × 10−6 after genomic control, adjusted for age and sex; supplementary Fig. 1 and designated in bold in supplementary Table 1, available in an online appendix). Among these 413 GWAS subjects, rs10500331 was also associated with BMI (P = 8.1 × 10−5 after genomic control, adjusted for age and sex; Table 2 and supplementary Table 1). To validate this GWAS association, rs10500331 was genotyped in a longitudinally studied, full-heritage Pima Indian population-based sample (n = 3,234) where individuals had multiple measures of BMI (description of the subjects is given in Table 1). Rs10500331 was associated with BMI in this full-heritage Pima Indian population sample (P = 1.9 × 10−7) and remained significant after excluding all subjects that overlapped with the initial GWAS study (nonoverlapping with GWAS full-heritage sample, n = 2,843; P = 1.9 × 10−5) (Table 2). Although independently replicated, these associations do not quite meet the proposed threshold for genome-wide significance of P < 7 × 10−8 (39). To further substantiate these associations by ruling out potential confounding effects of population stratification, we used the family structure of these samples and performed a within-family analysis, where rs10500331 was again associated with BMI in the initial GWAS sample (P = 5.3 × 10−2, supplementary Table 1), the entire full-heritage Pima Indian population sample, and the population sample after excluding the overlapping GWAS subjects (P = 7.4 ×10−3 and 3.2 ×10−2, respectively) (supplementary Table 2).
Rs10500331 maps within intron 1 of the A2BP1 gene, and several other variants within A2BP1 also showed significant associations with percent body fat and BMI in the GWAS study (supplementary Table 1). To directly examine A2BP1 as a candidate gene for obesity in Pima Indians, all exons and 2 kb of the upstream region of this gene were sequenced in 24 Pima Indians selected for being obese or nonobese. Twelve variants were identified of which two were rare novel substitutions (frequencies of the minor alleles = 0.03 and 0.09; sequences are provided in supplementary Table 2). An additional 108 variants spanning A2BP1 were then selected for genotyping in the full-heritage Pima Indian population sample (n = 3,234). The 108 variants consisted of 66 tag SNPs (minor allele frequency ≥ 0.15 and a pairwise r2 ≥ 0.8) from our previous 100K GWAS, 34 variants selected from our ongoing 1M GWAS, and 8 variants identified by sequencing including the two novel variants. Linkage disequilibrium plots (r2 and D′) for all 109 variants (including rs10500331) are shown in supplementary Fig. 2, available in an online appendix. Associations for all 109 variants with BMI, using both general and within-family analytical models, are shown for the entire full-heritage Pima Indian population sample to preserve power (n = 3,234), as well as for the n = 2,843 nonoverlapping with GWAS sample (supplementary Table 2). Several variants displayed modest associations (general and within-family analyses) in both samples; however, none of the associations was as strong as that for rs10500331.
Two variants, rs10500331 and rs12924838, which are in high linkage disequilibrium in full-heritage Pima Indians but not Caucasians (D′ = 0.96, r2 = 0.92 in Pima and D′ = 0.83, r2 = 0.25 in Caucasians; Fig. 1B and C) were significantly and reproducibly associated with BMI in Pima Indians (Table 2). These variants were further evaluated in four additional cohorts of European ancestry including French adult case/control subjects (1), French children case/control subjects (1), Amish families (28), and German school children case/control subjects (29). There was no evidence of association of rs10500331 with obesity in the French adult or children case/control subjects nor was there an association of this variant with BMI in the Amish or German school children case/control subjects (Table 2); however, rs12924838 was nominally associated with obesity in the French adult case/control subjects (P = 0.03) and when all of the European data were combined (n = 4,965, P = 0.02) (Table 2). Although neither rs10500331 nor rs12924838, which both map within intron 1 of A2BP1, appear to be convincingly associated with obesity or BMI in these European cohorts, a prior GWAS for severe obesity using case/control subjects of either French children or French adults identified several other variants within intron 1 of A2BP1 that were significantly associated with severe obesity (1). In the French children case/control subjects stage 1 samples, rs8054147 displayed the strongest association with obesity (P = 9.2 × 10−6, Fig. 2), whereas in the French adult case/control subjects stage 1 samples, rs4786847 had the strongest association (P = 1.9 × 10−10, Fig. 2). The striking association of rs4786847 with obesity was specific for the stage 1 French adult sample. For the stage 2 sample, which included 519 obese children and 566 lean young adults of French origin, 377 obese children and 731 lean children of German origin, 135 obese adults and 794 lean adults of French origin, 1,036 obese adults and 320 randomly selected adults of Swiss origin, a general population of 5,291 Finnish children, and a general population of 4,417 French adults, the association of rs4786847 with obesity or BMI was nominal (all stage 2 children P = 0.005, all stage 2 adults P = 0.76, entire stage 2 sample P = 0.03) (1).
To determine whether the associations observed with BMI in the Pima Indians represent a signal specific for Native Americans, five variants (rs9302818, rs10500331, rs8052357, rs12924838, and rs1946127) with the strongest associations with BMI in the full-heritage Pima Indians, and one variant (rs4786847) most strongly associated with BMI in the French adults, were genotyped in a second population-based sample of 2,531 individuals who were predominately Native Americans of mixed-heritage. Although none of the five variants most strongly associated with BMI in the full-heritage Pima Indians replicated in this mixed-heritage Native American sample, rs4786847, which had the strongest association in the French adult case/control subjects (P = 1.9 × 10−10), modestly replicated (P = 0.02, Table 3). Combining the full-heritage Pima Indian and mixed-heritage Native American population-based samples provided strong associations with BMI for all six variants; however, only the association with rs4786847 was strengthened from the combination of the two samples, whereas the other associations were solely due to the full-heritage Pima Indian sample (Table 3). European genotypic data were additionally available on three of these variants, making an “all-sample” (i.e., subjects in Table 1) analysis possible. All-sample P values for these three variants ranged from 0.02 to 0.0002 (Table 3), where significance was largely derived from a single sample.
A2BP1 is expressed in various tissues including hypothalamus, a major tissue in body weight regulation (Fig. 3), and it has also been reported to be expressed in brain, heart, and skeletal muscle tissue (21). To functionally investigate a possible role of A2BP1 in hypothalamic body weight regulation, siRNA that target the mouse A2bp1 gene were used to knockdown A2bp1 expression in a mouse embryonic hypothalamic cell line (N-41) and mRNA levels of five target genes were assessed by RT-PCR. These five genes included Atxn2, which encodes the binding partner of A2bp1 and has been implicated in human hyperphagia (23), and four additional genes, Insr, Lepr, Npy1r, and Mc4r, known to function in key pathways of central regulation of energy balance and known to be expressed in N-41 cells. RT-PCR of A2bp1 was also used to assess the efficiency of the siRNA knockdown.
We found that a 75% reduction in A2bp1 expression in the N-41 cells led to a 53, 60, and 75% decrease in gene expression levels for Atxn2, Insr, and Mc4r, respectively, whereas expression levels for Lepr and Npy1r were largely unaffected (Fig. 4).
The associations between variants in A2BP1 with both percent body fat and BMI in our 100K GWAS and the evidence for association of these variants with longitudinally measured BMI in a large population-based sample of full-heritage Pima Indians, along with the obese phenotypes observed with Atxn2 knockout mice (24,25) and high expression levels of A2BP1 in the hypothalamus, leads us to speculate that A2BP1 has a role in body weight regulation. However, the highly significant associations obtained with different variants in each of the Pima Indian, French adult, and French children studies is inconsistent with a single common variant giving rise to this phenotype. Among populations representing different ethnicities, lack of reproducibility with a specific variant may be due to the existence of an untyped causal variant with differing linkage disequilibrium patterns between ethnic groups (40). Pezzolesi et al. describe a similar pattern where different variants across the same locus (ELMO1) in different ethnic groups, Caucasians (41), African-Americans (42), and Japanese (43), are associated with diabetic nephropathy (41). They suggest that this allelic heterogeneity is probably the result of different ancestral genetic backgrounds and propose that rare variants in ELMO1 may be common to each ethnic group and are being tagged by the common variants found in the individual studies (41). This concept, however, cannot explain strong associations of different variants in French adults and in French children. Another hypothesis more consistent with our observations is that strong, yet distinct, associations within a region of a biologically relevant gene would be observed if there are multiple rare causative variants that can occur within a single ethnic group. These rare variants, all of which could affect a potential functionally important region (e.g., intron 1 of A2BP1), may be more highly represented by chance in one sample set than in another and, thus, provide association signals with different tag SNPs in one group of individuals than in another. Deep resequencing across intron 1 of A2BP1 in each of the different populations may be the best approach to test this hypothesis. At present, the costs of deep resequencing in a large number of subjects make this line of investigation difficult. Therefore, we chose to investigate the function of A2BP1 directly based on the current association data and the observation that atxn2−/− mice become obese.
A2BP1 is a RNA-binding protein involved in regulating tissue-specific alternative splicing by binding the RNA cis-regulatory element UGCAUG (20). A2BP1 binding to UGCAUG elements downstream of the exon enhances exon inclusion, while binding to UGCAUG elements upstream of the exon represses exon inclusion (20). The UGCAUG motif is highly enriched in brain-specific intronic regions flanking exons and alternative exons (44). A recent genome-wide survey for the UGCAUG element identified 1,103 genes with at least one predicted UGCAUG element. Included in this gene list were A2BP1 (five elements), ATXN2 (two elements), and INSR (two elements) (44). In addition to binding the UGCAUG splicing motif, A2BP1 is a binding partner for the ATXN2 protein (21), which also contains predicted RNA binding and RNA splicing motifs and is thought to be involved in mRNA degradation and regulating translation (45,46).
In the human hypothalamus, LEPR and INSR sense the peripheral leptin and insulin signals to control food intake and energy homeostasis through POMC-MC4R and NPY-Y1R pathways. Central nervous system deficiencies of these pathways are known to affect energy homeostasis and result in severe obesity (47,48). After knockdown of A2bp1 in the N-41 mouse embryonic hypothalamic cells, we observed a decrease in both INSR and MC4R expression. Knockdown of A2BP1 also resulted in a decrease in Atxn2 gene expression, and it has been shown by others that Atxn2 knockout mice become obese (24,25). However, the mechanism whereby deficiency of A2BP1 expression leads to a decrease in mRNA levels for these three genes is unknown. Because both ATXN2 and INSR have predicted UGCAUG splicing elements (44), mRNA splicing for the two genes may be affected by a decrease in A2BP1, leading to unstable transcripts that are subsequently degraded. Unlike ATXN2 and INSR, the transcript for Mc4R codes for only one exon and does not appear to contain binding sites for A2BP1. Therefore, instead of affecting mRNA stability, the reduction in A2BP1 may result in the decrease of Mc4R indirectly by affecting some transcriptional regulatory protein involved in the expression of Mc4R.
In conclusion, GWAS data in Pima Indians and French Caucasians suggest that multiple variants in A2BP1 may exist that contribute to human obesity, and A2bp1 knockdown studies suggest that deficiency of A2bp1 could play a role in the hypothalamic regulation of feeding. However, deep resequencing of A2BP1 and further in vivo studies are necessary to confirm the biological role of this gene in the pathogenesis of obesity.
This work was supported by the intramural research program of NIDDK, National Institutes of Health, and NIH Grants R01-DK-54261 (to A.S.), P30-DK-072488 (Clinical Nutrition Research Unit of Maryland), and P60-DK-079637 (Baltimore Diabetes Research and Training Center). Grant support was also provided by the American Diabetes Association (individually to C.B. and A.S.). Additional support was provided by grants from the Deutsche Forschungsgemeinschaft (DFG) KFO 152: project KO 3512/1-1, 1264/10-1, and the European Community integrated project grant “PIONEER.” No potential conflicts of interest relevant to this article were reported.
L.M. researched data, contributed to discussion, and wrote the manuscript. R.L.H., A.K., and C.B. researched data, contributed to discussion, and reviewed/edited the manuscript. M.T.T. reviewed/edited the manuscript. Y.L.M. and P.W.F. contributed to discussion and reviewed/edited the manuscript. B.P.K. and J.M.P. researched data. D.M., M.F., W.K., S.K., W.C.K., P.K., P.F., and A.R.S. researched data and reviewed/edited the manuscript. L.J.B. researched data, contributed to discussion, wrote the manuscript, and reviewed/edited the manuscript.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
- Received October 30, 2009.
- Accepted August 8, 2010.
- © 2010 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.